EyeD Pharma
EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life.
EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life.
EyeD Pharma has raised $51.0M across 1 round. Its most recent round was a Venture - Series Unknown of $51.0M in Dec 2021. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
EyeD Pharma is featured in
Similar companies
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock. Through a combination of advanced research, animal science, and biotech, Animab produces products that enhance animal health, decrease expenses, and promote sustainability. Specifically, Animab offers a safe and sustainable solution for safeguarding the intestinal health of piglets after weaning. The antibodies in Animab mimic secretory IgA, a natural antibody passed on through colostrum and milk to safeguard nursing animals.
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations of selective HDAC6 inhibitors that can be used to treat axonopathies like Charcot Marie Tooth disease. These new compounds show promise in protecting against nerve degeneration and aiding in the repair of peripheral myelin and axons.
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges of cell-based treatments.
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding specific molecules to AAV vectors, the company is able to develop more precise and safer gene therapies, a major breakthrough in the industry. Established as a spin-off from KU Leuven and Trellis, Tavira is utilizing cutting-edge research to enhance gene therapy through modular AAV capsid technologies.
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic monoclonal immunizer particles ("agomAbs") animate atomic and cell fix systems that can possibly reestablish organ capability in patients with fibrotic, fiery, immune system and degenerative illnesses.
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global Unmet Medical Needs : Available, Affordable, Sustainable. BioSourcing changes the design paradigm of these new biotherapeutics thanks to the mastery of several breakthrough technologies including genome editing (CRISPR). The BioSourcing disruptive approach leads to a drastic reduction in capital requirements and production costs, especially for large volumes, as well as an improvement in the quality/efficiency of biopharmaceuticals through better glycosylation. BioSourcing strongly contributes to sustainable development, in particular in drasticly reducing the carbon footprint. BioSourcing is a fully operational biotechnology company, based in Liège, Belgium. Its team is made up of the best scientists, international experts in their field and has developed strategic partnerships with leaders in the pharmaceutical and biotechnology industry.
Hedera-22 broadened its focus to incorporate the discovery of natural products using internal bioinformatics prediction technologies.
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical needs that have not been met. The company uses its unique CONFO® technology to stabilize the functional shapes of GPCRs, providing a strong foundation for drug discovery. By stabilizing the active state conformations of these receptors, Confo Therapeutics is able to uncover important structural details that were previously unknown, leading to the development of new agonists for improved therapeutic treatments.
Vivagran is a company that specializes in biotechnology and focuses on creating and selling high-quality branded cereals that cater to consumer preferences.
Cognivia creates analytical software that enhances and expedites the clinical development of new medications.
Oxurion is a biopharmaceutical company focused on developing advanced eye treatments to improve vision in patients with conditions like diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.